NCT00076180View on ClinicalTrials.gov

Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 1, 2004

Primary Completion Date

November 12, 2010

Study Completion Date

January 9, 2019

Conditions
T-Cell Large Granular Lymphocytic LeukemiaLeukemia, T-Cell Large Granular Lymphocytic
Interventions
BIOLOGICAL

Hu-MiK-Beta-1

Hu-MiK-Beta-1 administered as an intravenous infusion over 90- minutes.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00076180 - Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter